Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial assessing tetravalent bispecific anti-VEGFA (vascular endothelial growth factor A) / ANG2 (angiopoietin 2) antibody in neovascular age-related macular degeneration (nAMD)

Next Previous
Search
Trial Profile

A clinical trial assessing tetravalent bispecific anti-VEGFA (vascular endothelial growth factor A) / ANG2 (angiopoietin 2) antibody in neovascular age-related macular degeneration (nAMD)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 05 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eye-disorder-bispecific-antibody-therapy-China-Medical-System (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions

    • Most Recent Events

    • 05 May 2023 New trial record
    • 27 Apr 2023 According to China Medical System media release, the tetravalent bispecific anti-VEGFA (vascular endothelial growth factor A) / ANG2 (angiopoietin 2) antibody for intravitreal injection has been granted an approval for drug clinical trials issued on 27 April 2023 by National Medical Products Administration of the Peoples Republic of China (NMPA) and agreed to conduct this clinical trial

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top